Intellia Therapeutics, Inc.
NTLA · NASDAQ
Earnings history and estimates
Reported and estimated revenue, EPS and post-earnings movement.
| Period | Date | Revenue actual | Revenue estimate | EPS actual | EPS estimate | 1D move |
|---|---|---|---|---|---|---|
| 2026 Q2 | August 6, 2026 | — | 12.98M | — | -0.80 | — |
| 2026 Q1 | May 11, 2026 | 15.05M | 13.81M | -0.81 | -0.92 | +4.43% |
| 2025 Q4 | February 26, 2026 | 23.02M | 11.98M | -0.83 | -0.99 | +6.41% |
| 2025 Q3 | November 6, 2025 | 13.78M | 12.17M | -0.92 | -1.02 | -22.73% |
| 2025 Q2 | August 7, 2025 | 14.25M | 14.06M | -0.99 | -1.03 | +0.79% |
| 2025 Q1 | May 8, 2025 | 16.63M | 11.93M | -1.10 | -1.26 | +13.58% |
| 2024 Q4 | February 27, 2025 | 12.87M | 10.86M | -1.24 | -1.32 | +0.56% |
| 2024 Q3 | November 7, 2024 | 9.11M | 8.90M | -1.34 | -1.37 | -0.37% |
| 2024 Q2 | August 8, 2024 | 6.96M | 19.16M | -1.31 | -1.21 | +5.02% |
| 2024 Q1 | May 9, 2024 | 28.94M | 11.50M | -1.06 | -1.35 | +8.09% |
| 2023 Q4 | February 22, 2024 | 1.92M | 12.83M | -1.46 | -1.47 | +1.12% |
| 2023 Q3 | November 9, 2023 | 11.99M | 12.45M | -1.38 | -1.52 | -12.27% |
| 2023 Q2 | August 3, 2023 | 13.59M | 12.08M | -1.40 | -1.32 | -1.56% |
| 2023 Q1 | May 4, 2023 | 12.61M | 11.83M | -1.17 | -1.41 | +13.14% |
| 2022 Q4 | February 23, 2023 | 13.57M | 11.33M | -1.40 | -1.40 | +0.08% |
| 2022 Q3 | November 3, 2022 | 13.27M | 11.89M | -1.49 | -1.31 | +1.00% |